{"id":2338,"date":"2015-05-01T12:06:00","date_gmt":"2015-05-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/hohe-dosen-ibuprofen-erhoehen-kardiovaskulaere-risiken"},"modified":"2015-05-01T12:06:00","modified_gmt":"2015-05-01T10:06:00","slug":"hohe-dosen-ibuprofen-erhoehen-kardiovaskulaere-risiken","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/hohe-dosen-ibuprofen-erhoehen-kardiovaskulaere-risiken","title":{"rendered":"Hohe Dosen Ibuprofen erh\u00f6hen kardiovaskul\u00e4re Risiken"},"content":{"rendered":"<p>Das Pharmacovigilance Risk Assessment Committee (PRAC; Ausschuss f\u00fcr Risikobewertung) der Europ\u00e4ischen Arzneimittel-Agentur (EMA) hat in einem Review die kardiovaskul\u00e4ren Risiken (Myokardinfarkt und Schlaganfall) von Ibuprofen an Hand von Originalpublikationen und Metaanalysen \u00fcberpr\u00fcft (1): Nach dieser Analyse sind bei hohen Tagesdosen (\u2265 2400 mg) die Risiken leicht erh\u00f6ht und \u00e4hnlich hoch wie bei anderen nichtsteroidalen Antiphlogistika [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das Pharmacovigilance Risk Assessment Committee (PRAC; Ausschuss f\u00fcr Risikobewertung) der Europ\u00e4ischen Arzneimittel-Agentur (EMA) hat in einem Review die kardiovaskul\u00e4ren Risiken (Myokardinfarkt und Schlaganfall) von Ibuprofen an Hand von Originalpublikationen und Metaanalysen \u00fcberpr\u00fcft (1): Nach dieser Analyse sind bei hohen Tagesdosen (\u2265 2400 mg) die Risiken leicht erh\u00f6ht und \u00e4hnlich hoch wie bei anderen nichtsteroidalen Antiphlogistika [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,684,495,60,1272,77,76,71,180,68,502,498,65,256,564,562,563,565,4647,4648,56,254,4410],"class_list":["post-2338","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-apoplektischer-insult","tag-arteriosklerose","tag-ass","tag-azetylsalizylsaeure","tag-herzinfarkt","tag-herzinsuffizienz","tag-hirninfarkt","tag-ibuprofen","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-nebenwirkungen","tag-nichtsteroidale-antiphlogistika","tag-nichtsteroidale-antirheumatika","tag-nsaid","tag-nsar","tag-pharmacovigilance-risk-assessment-committee","tag-prac","tag-schlaganfall","tag-uaw","tag-unerwuenschte-arzneimittelereignisse"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2338"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2338\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}